Tralokinumab Demonstrated a Consistent Safety Profile With up to 42 Months of Treatment in Moderate-to-Severe Atopic Dermatitis: Including Adverse Events of Special Interest. J of Skin 2022, 6 (6), s79. https://doi.org/10.25251/skin.6.supp.79.